Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families.
Hemostemix Inc.
TSXV:HEM
0.16
cad
Volume 17500
Change
-8.57 %
Prev. Close 0.18 cad
OTCQB:HMTXF
0.11
usd
Volume 17760
Change
0.00 %
Prev. Close 0.11 usd
Disclaimer: All stock information on InvestorIntel.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.
InvestorIntel Features on Hemostemix Inc.
-
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Hemostemix steps into the new year with capital and its critical clinical study data in hand
With a new management team spearheading Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), the Company started 2021 with…